|
|
||||||||
1 Departments of Medicine, Biochemistry, and Radiology, and Center for Magnetic Resonance Research, University of Minnesota, Minneapolis 55455; and 2 Department of Veterans Affairs Medical Center, Minneapolis, Minnesota 55417
This study
was performed to determine whether the fall in myocardial high-energy
phosphates (HEP) that occurs during high workstates can be ascribed to
either inadequate glycolytic pyruvate generation and conversion to
acyl-CoA or limitation of long-chain fatty acid transport into the
mitochondria. This was tested by using infusions of either pyruvate or
butyrate in anesthetized dogs. Pyruvate was used because it bypasses
the glycolytic sequence of reactions, activates pyruvate dehydrogenase,
and increases mitochondrial NADH concentration ([NADHm])
in isolated myocardium, whereas butyrate enters the mitochondria
without need for transport by the rate-limiting, palmitoyl-carnitine
transporter. Increasing blood pyruvate from 0.16 ± 0.016 mM to
>3 mM did not alter baseline HEP levels determined with
31P nuclear magnetic resonance, but caused an increase in
the rate-pressure product and a modest increase in myocardial oxygen
consumption (M
O2). Infusion of
dobutamine + dopamine (each 20 µg · kg
1 · min
1 iv)
increased M
O2 and caused decreases of
myocardial phosphocreatine (PCr)/ATP. Pyruvate partially reversed the
decrease of HEP levels produced by catecholamine stimulation, whereas
butyrate had no effect. Neither pyruvate nor butyrate caused an
increase of M
O2 during catecholamine
infusion. Deoxymyoglobin was not detected by 1H magnetic
resonance spectroscopyy in any group. The data demonstrate that
carbon substrate availability to the mitochondria is not the only cause
of the reduction of PCr/ATP that occurs at high workstates.
Supplemental pyruvate (but not butyrate) attenuated the reduction of
PCr/ATP during the high workstates; this may have resulted from direct
effects on intermediary metabolism or from other effects such as the
free radical scavenging activity of pyruvate.
catecholamines; oxygen consumption; magnetic resonance spectroscopy
This article has been cited by other articles:
![]() |
F. Wu, J. Zhang, and D. A. Beard Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism PNAS, April 28, 2009; 106(17): 7143 - 7148. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Olson, O. M. Hyyti, G. A. Cohen, X.-H. Ning, M. Sadilek, N. Isern, and M. A. Portman Superior cardiac function via anaplerotic pyruvate in the immature swine heart after cardiopulmonary bypass and reperfusion Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2315 - H2320. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Wu, E. Y. Zhang, J. Zhang, R. J. Bache, and D. A. Beard Phosphate metabolite concentrations and ATP hydrolysis potential in normal and ischaemic hearts J. Physiol., September 1, 2008; 586(17): 4193 - 4208. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Belke, E. Swanson, J. Suarez, B. T. Scott, A. E. Stenbit, and W. H. Dillmann Increased expression of SERCA in the hearts of transgenic mice results in increased oxidation of glucose Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1755 - H1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Portman, K. Qian, J. Krueger, and X.-H. Ning Direct action of T3 on phosphorylation potential in the sheep heart in vivo Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2484 - H2490. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. O'Donnell, R. K. Kudej, K. F. LaNoue, S. F. Vatner, and E. D. Lewandowski Limited transfer of cytosolic NADH into mitochondria at high cardiac workload Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2237 - H2242. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. J. Woo, M. D. Taylor, J. E. Cohen, V. Jayasankar, L. T. Bish, J. Burdick, T. J. Pirolli, M. F. Berry, V. Hsu, and T. Grand Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1262 - 1269. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kristo, Y. Yoshimura, J. Niu, B. J. Keith, R. M. Mentzer Jr., R. Bunger, and R. D. Lasley The intermediary metabolite pyruvate attenuates stunning and reduces infarct size in in vivo porcine myocardium Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H517 - H524. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |